New acid blocker may beat standard drug for stomach bug
NCT ID NCT07165444
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study compares two types of acid-reducing drugs—vonoprazan (a newer drug) and rabeprazole (a standard drug)—when used as part of a 10-day combination therapy for H. pylori infection. About 320 adults with confirmed H. pylori will be randomly assigned to one of the two treatments. The main goal is to see which drug leads to higher eradication rates, with fewer side effects and better patient adherence.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
vonoprazan (potassium-competitive acid blocker) and rabeprazole (proton pump inhibitor)
What this could lead to
If successful, this could show that vonoprazan is more effective than rabeprazole at eradicating H. pylori when used in combination therapy, potentially improving treatment success rates.
What could go wrong
This is a relatively small, single-center trial. The results may not apply to all populations, and the study does not test long-term outcomes or recurrence.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POTASSIUM-COMPETITIVE ACID BLOCKER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tanta University
RECRUITINGTanta, El-Gharbia, 31527, Egypt
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact